Damaged joints and bones in mice with hemophilia benefit from extended activity of coagulation factor IX, research shows. The study, “Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis,” was published in the journal Blood. Patients with hemophilia often have…
Search results for:
Catalyst Biosciences, developers of protease therapeutics for serious hemostasis and anti-complement conditions, and CMC ICOS Biologics, Inc., which manufactures therapeutic proteins, have partnered for the manufacture of a next generation hemophelia drug. Catalyst is developing CB 813d, a longer-acting Factor VIIa drug for hemophilia A and B inhibitor patients. “We selected CMC Biologics…
Genentech will present more than 60 abstracts at the 58th American Society of Hematology Annual Meeting (ASH 2016). Nine of Genentech’s approved or investigational medicines will be featured, including Gazyva (obinutuzumab), Rituxan (rituximab), Venclexta (venetoclax) and emicizumab, the company’s investigational drug in hemophilia. More specifically, Genentech will present…
Social Clips
What Is Acquired Hemophilia?
The majority of hemophilia cases are genetic, affect males and are diagnosed fairly early in childhood. However, there are rare cases of hemophilia that develop later in life and are called “acquired hemophilia.” MORE: Four hemophilia screening tests. Acquired hemophilia is an autoimmune disease where the immune system attacks blood clotting factor…
The severity levels of hemophilia are determined by the level of residual/remaining clotting factor (factor VIII or factor IX) activity in the patient’s blood, which is denoted by the percentage of factor activity in the blood (or international units per ml of blood – IU/ml). According to the World Federation of Hemophilia,…
Four years after treatment with the gene therapy Hemgenix (etranacogene dezaparvovec), most people with hemophilia B aren’t taking preventive therapies and annual bleeding rates remain substantially reduced, new data from the Phase 3 HOPE-B trial shows. CSL Behring, which markets Hemgenix, presented the results at the 18th…
Dear hemophilia, Truth be told, I hate you sometimes. I especially hate you when you suddenly pop out of nowhere and find ways to ruin my husband’s life. I hate you when you encroach on plans made weeks in advance; long-standing plans that were carefully and painstakingly thought out. As…
While there is no cure for hemophilia, it is very possible to live with this genetic bleeding disorder and maintain a good quality of life. Proper nutrition and weight management combined with a safe and effective exercise plan monitored by a medical professional can make…
First meetings are always awkward, aren’t they? Well, I have the perfect icebreaker: Did you know that my husband, Jared, has hemophilia? Most people I meet are taken aback by this. Those with a thirst for knowledge are often intrigued. How often does one meet a person with hemophilia,…
The European Commission has granted conditional marketing authorization to BioMarin’s one-time gene therapy Roctavian (valoctocogene roxaparvovec) as a treatment for adults with severe hemophilia A who have neither inhibitors nor detectable antibodies against adeno-associated virus serotype 5 (AAV5). The decision, which comes a couple of months after a…